Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF(V600E) or BRAF(V600K) mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study
Robert, C. Kicinski, M. Dutriaux, C. Routier, É. Govaerts, A. S. Bührer, E. Neidhardt, E. M. Durando, X. Baroudjian, B. Saiag, P.
Robert, C.
Kicinski, M.
Dutriaux, C.
Routier, É.
Govaerts, A. S.
Bührer, E.
Neidhardt, E. M.
Durando, X.
Baroudjian, B.
Saiag, P.
Abstract
BACKGROUND: Current first-line treatment for patients with metastatic melanoma with BRAF(V600E) or BRAF(V600K) mutations includes immunotherapy with immune checkpoint inhibitors and targeted therapy; however, the optimal sequencing of these treatments is unclear. We aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors. METHODS: This open-label, randomised, controlled, phase 2 trial (EBIN) was conducted at 37 centres in eight European countries. Eligible patients were 18 years or older and had previously untreated, unresectable, stage III or IV melanoma with BRAF(V600E) or BRAF(V600K) mutations and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to one of two groups. Those in the induction group received targeted therapy (oral encorafenib 450 mg once a day plus oral binimetinib 45 mg twice a day for 12 weeks) followed by immune checkpoint inhibitors (intravenous nivolumab 3 mg/kg plus intravenous ipilimumab 1 mg/kg once every 3 weeks for four doses, followed by intravenous nivolumab 480 mg once every 4 weeks until unacceptable toxicity, disease progression, or 2 years of treatment). Patients in the control group received immune checkpoint inhibitors as above without any induction targeted therapy. Randomisation was conducted using a minimisation technique and was stratified by centre and a variable defined using stage and lactate dehydrogenase activity. The primary outcome was progression-free survival in the intention-to-treat population. Safety was assessed in all patients who initiated the protocol treatment. In this Article we report the primary analysis. The study is registered with ClinicalTrials.gov, NCT03235245, and is ongoing. FINDINGS: Between Nov 12, 2018, and July 11, 2022, 271 patients were randomly assigned: 136 to the induction group and 135 to the control group. 103 (38%) patients were female, 168 (62%) were male, and the median age was 55 years (IQR 43-66). The median follow-up time was 21 months (IQR 13-33). There was no evidence of a longer progression-free survival in the induction group than in the control group (hazard ratio 0·87, 90% CI 0·67-1·12; p=0·36). The median progression-free survival was 9 months (95% CI 7-13) in the induction group and 9 months (5-14) in the control group. Grade 3-5 treatment-related adverse events occurred in 57 (42%) of 136 patients who started treatment in the induction group and in 42 (32%) of 131 patients who started treatment in the control group. The most common grade 3-4 treatment-related adverse event was hepatitis (17 [13%] of 136 patients in the induction group and nine [7%] of 131 patients in the control group). Serious treatment-related adverse events occurred in 45 (33%) of 136 patients in the induction group and 33 (25%) of 131 patients in the control group. There were three treatment-related deaths: two from cardiac events (heart failure and arrhythmia) in the induction group and one from meningitis in the control group. INTERPRETATION: The targeted-therapy induction regimen did not improve progression-free survival compared with first-line treatment with immune checkpoint inhibitors in unselected patients with advanced melanoma with BRAF(V600E) or BRAF(V600K) mutations. FUNDING: Bristol Myers Squibb and Pierre Fabre.
Authors
Robert, C.
Kicinski, M.
Dutriaux, C.
Routier, É.
Govaerts, A. S.
Bührer, E.
Neidhardt, E. M.
Durando, X.
Baroudjian, B.
Saiag, P.
Gaudy-Marqueste, C.
Ascierto, P. A.
Arance, A.
Russillo, M.
Perrot, J. L.
Mortier, L.
Aubin, F.
Dalle, S.
Grange, F.
Muñoz-Couselo, E.
Mary-Prey, S.
Amini-Adle, M.
Mansard, S.
Lebbe, C.
Funck-Brentano, E.
Monestier, S.
Eggermont, A. M. M.
Oppong, F.
Wijnen, L.
Schilling, B.
MandalÁ, M.
Lorigan, P.
van Akkooi, A. C. J.
Kicinski, M.
Dutriaux, C.
Routier, É.
Govaerts, A. S.
Bührer, E.
Neidhardt, E. M.
Durando, X.
Baroudjian, B.
Saiag, P.
Gaudy-Marqueste, C.
Ascierto, P. A.
Arance, A.
Russillo, M.
Perrot, J. L.
Mortier, L.
Aubin, F.
Dalle, S.
Grange, F.
Muñoz-Couselo, E.
Mary-Prey, S.
Amini-Adle, M.
Mansard, S.
Lebbe, C.
Funck-Brentano, E.
Monestier, S.
Eggermont, A. M. M.
Oppong, F.
Wijnen, L.
Schilling, B.
MandalÁ, M.
Lorigan, P.
van Akkooi, A. C. J.
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Robert C, Kicinski M, Dutriaux C, Routier É, Govaerts AS, Bührer E, et al. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF(V600E) or BRAF(V600K) mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study. The Lancet Oncology. 2025 Jun;26(6):781-94. PubMed PMID: 40449497. Epub 2025/06/01. eng.